Acute pulmonary edema due to sympathetic surge and increased peripheral vascular resistance often present to the emergency department (ED) with markedly elevated blood pressure, severe dyspnea, and desaturation. This condition is known as "SCAPE" (sympathetic crashing acute pulmonary edema). We present three SCAPE patients who were successfully treated with high-dose nitroglycerin (NTG) and bilevel positive airway pressure (BiPAP) ventilation. All three patients presented with respiratory failure on arrival but rapidly improved after treatment and did not require endotracheal intubation or admission to the intensive care unit (ICU). SCAPE patients usually present to the ED with extreme respiratory distress associated with diaphoresis, restlessness, and high blood pressure. Emergency physicians must know how to manage SCAPE with high-dose nitrates and NIPPV (noninvasive positive pressure ventilation) because, when treated promptly, one will not only save a life but also obviate the need for endotracheal intubation and ICU admission.
Introduction
Organic nitrates, such as nitroglycerin (NTG), isosorbide-5-mononitrate and isosorbide dinitrate, are strong vasodilators traditionally used in the treatment of patients with congestive heart failure, acute coronary syndrome, or severe hypertension. 1 Patients with acute congestive heart failure complicated with pulmonary edema often present to the emergency department (ED) with markedly elevated blood pressure, severe dyspnea, and desaturation. Such respiratory emergencies are the result of a sympathetic surge with markedly increased peripheral vascular resistance. This condition is known as "SCAPE" (sympathetic crashing acute pulmonary edema). 2 We present three SCAPE patients who were successfully treated with high-dose nitroglycerin (NTG) and bilevel positive airway pressure (BiPAP) ventilation. All three patients presented with respiratory failure on arrival but rapidly improved after treatment and did not require endotracheal intubation or admission to the intensive care unit (ICU). High-doses of NTG are well tolerated in our patients. Recent studies also demonstrate that nitrate tolerance may be the result of supraphysiological and suprapharmacological NTG doses. On the other hand, low doses of NTG are less likely to induce tolerance 1 .
Case presentations

Case 1
A 65-year-old female with past history of heart failure and hypertension presented to the ED with acute dyspnea and chest tightness. On examination, she appeared anxious and diaphoretic. Her BP was 213/91 mm Hg, PR 103 bpm, RR 36/min, SpO2 92% (using high-flow O2 mask), and temperature 36 C. Orthopnea and bilateral basal rales were also noted. ECG showed sinus tachycardia with nonspecific ST-T changes. Chest X-ray and beside ultrasound are diagnostic of acute pulmonary edema. Blood tests were unremarkable. BiPAP ventilation was initiated immediately after 3 consecutive tablets of sublingual NTG (NITROSTAT 0.6 mg/tab) were given without success. The patient continued to have dyspnea, diaphoresis and markedly elevated BP (223/100 mm Hg). Push-doses (1 mg every 2 minutes) of intravenous NTG were administered, followed by IV NTG low-dose infusion at 40 mg/min.
After receiving a total dose of 6 mg NTG boluses over 15 minutes, her vital signs normalized (BP 135/86 mm Hg, PR 88 bpm) and we were able to discontinue the BiPAP machine. The patient was admitted to the general ward and was later confirmed to have congested heart failure. After admission, she was treated with furosemide and digoxin with good response and was discharged several days later (see Fig. 1 ).
Case 2
A 60-year-old male with history of hypertension, diabetes, and end-stage renal disease under regular hemodialysis, presented to our ED with severe shortness of breath for several hours. On arrival, his vital signs were BP 205/105 mm Hg, PR 116 bpm, RR 30/min, temperature 36 C, and SpO2 89% (at room air). Physical examination revealed bilateral wheezing and basal rales. Pulmonary edema was confirmed on chest radiograph. The dyspnea deteriorated despite high-flow oxygen use and 3 subsequent tablets of NTG given sublingually. He was rapidly connected to a BiPAP machine and 4 consecutive push-doses (1 mg every 2 minutes) of IV NTG were given until the dyspnea subsided. Shortly after the NTG boluses, his BP was lowered to 140/82 mm Hg and he was able to come off the BiPAP machine. Hemodialysis was scheduled 4 hours after his arrival and he was discharged uneventfully after the dialysis (see Fig. 2 ).
Case 3
A 65-year-old male presented to the ED with progressive dyspnea and profuse sweating. He had HTN, DM, and ESRD with regular dialysis. His vital signs were BP 198/86 mm Hg, PR 143 bpm, RR 36/min, SPO2 60%, and temperature 35 C (at room air). Physical examination showed bilateral moist rales and chest radiograph confirmed lung edema. ECG showed sinus tachycardia and blood tests were unremarkable. Treatment with high-flow oxygen and 3 sublingual NTG was unsuccessful. Subsequently, BiPAP and 3 boluses of NTG (1 mg every 2 minutes) successfully stabilized the patient and prevented the need of endotracheal intubation. The patient's vital signs stabilized (BP 141/89, PR 98) prior to hemodialysis and he was able to breath smoothly (RR 18/min, SpO2 96%) through O2 nasal prongs. He was discharged uneventfully after hemodialysis (see Fig. 3 ).
Discussion
Life-threatening acute pulmonary edema may not be caused by fluid accumulation but rather fluid redistribution because of heart failure and increased systemic vascular resistance from sympathetic neurohormonal activation. Previous studies also demonstrated that the vasoconstriction can be prevented by angiotensin Iconverting enzyme inhibitor (e.g. captopril), suggesting that this phenomenon is mediated by angiotensin II. 3 The activation of renin-angiotensin-aldosterone system (RAAS) results in even higher peripheral vascular resistance and increased sodium and water reabsorption. Both worsen cardiac function and decrease pulmonary venous return. As a result, intravascular fluid shift into the pulmonary interstitium and alveoli, causing hypoxia, dyspnea, and further sympathetic surge. 2, 4 Therefore, sympathetic crashing acute pulmonary edema (SCAPE) is a better terminology for this subset of patients.
2,4,5
In SCAPE, the abrupt redistribution of fluid into the lungs may occur even when the patient is hypovolemic or euvolemic. Therefore, the emphasis in treating pulmonary edema has shifted from diuretics to vasodilators, especially high-dose nitrates, combined with noninvasive positive pressure ventilation (NIPPV). 2, 6, 7 When treated promptly, patients with SCAPE will recover rapidly. More importantly, many unnecessary intubations and ICU admissions could be avoided by the high-dose NTG bolus approach. Conventionally, the usual dose of NTG in treating congestive heart failure (CHF) is 5e40 mg/min continuous infusion. For doses <250 mg/min, the effects NTG are predominantly venodilatory causing preload reduction. In treating CHF patients with profound hypertension and lung edema, NTG doses should exceed 250 mg/min in order to take effect (MAP reduction and fluid redistribution) rapidly via venous and arterial dilation. 7 In our protocol, high-dose NTG and BiPAP are the mainstay of treatment which should be started within minutes of the patient's arrival to the ED. Our NTG dosing protocol include 0.6 mg sublingual tablet up to 3 times followed by 1 mg intravenous boluses every 2 minutes as needed, up to 10 mg maximum. Contraindications to NTG use include severe aortic stenosis, recent use of phosphodiesterase type 5 inhibitors (e.g. sildenafil, tadalafil, vardenafil), hypertrophic obstructive cardiomyopathy, or hypotension at any time.
6,7
Conclusion
In conclusion, our cases demonstrated that SCAPE patients usually present to the ED with extreme respiratory distress associated with diaphoresis, restlessness, and high blood pressure (usually SBP > 180 mm Hg). Emergency physicians must know how to manage SCAPE with high-dose nitrates and NIPPV because, when treated promptly, one will not only save a life but also obviate the need for endotracheal intubation and ICU admission. Future prospective, randomized, multi-center trials are warranted to confirm the SCAPE hypothesis. 
